Sign Up for a Free Account
  • Updated 03.27.2018
  • Released 03.27.2018
  • Expires For CME 03.27.2021

Neuromuscular diseases: high cost of new treatments

Introduction

This article includes discussion of the high cost of new treatments for neuromuscular diseases and the Orphan Drug Act.

Overview

Neuromuscular diseases are on the forefront of therapeutic development. Three new disease-modifying therapies have been approved in the past 12 months for rare neuromuscular disorders, an unprecedented pace for any area of neurology. The favorable regulatory landscape for orphan disease has provided the impetus to invest in these disorders. However, the cost and intensity of these therapies have provided new challenges to physicians treating these debilitating illnesses. In this article, the authors describe the challenges and identify some solutions moving forward.

Key points

• Incentives within the Orphan Drug Act have promoted research in rare neuromuscular diseases.

• New disease-modifying therapies in neuromuscular disease are difficult to implement given the cost and route of administration.

• Initial implementation in multidisciplinary clinics may be the most feasible approach.

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com